Loading...

FITC anti-human CD69 Antibody

Pricing & Availability
Clone
FN50 (See other available formats)
Regulatory Status
RUO
Workshop
IV A91
Other Names
Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
FN50_FITC_060308
PMA + ionomycin stimulated (6 hours) human lymphocytes stained with FN50 FITC
  • FN50_FITC_060308
    PMA + ionomycin stimulated (6 hours) human lymphocytes stained with FN50 FITC
See FITC spectral data
Cat # Size Price Quantity Check Availability Save
310903 25 tests 39€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
310904 100 tests 86€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections2, immunofluorescence microscopy3, and spatial biology (IBEX)8,9.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
  3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
  4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496.
  5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Lin JR et al. 2018. eLife. 7 pii: e31657. PubMed
  2. Shifrut E et al. 2018. Cell. 175(7):1958-1971 . PubMed
  3. Gao R, et al. 2018. Oncoimmunology. 7:e1438108. PubMed
  4. Tanno H, et al. 2020. Sci Adv. 6:eaay9093. PubMed
  5. Nixon CC, et al. 2020. Cell Reports Medicine. 578(7793):160-165. PubMed
  6. Cohen O, et al. 2012. Int Immunol. 24:783. PubMed
  7. Finetti F, et al. 2015. J Cell Sci. 128: 2541 - 2552. PubMed
  8. Yukawa M, et al. 2020. J Exp Med. 217:00:00. PubMed
  9. Rydyznski Moderbacher C, et al. 2020. Cell. 183(4):996-1012.e19. PubMed
  10. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
  11. Lavaert M, et al. 2020. Frontiers in Immunology. 1.610416667. PubMed
  12. Pettmann J, et al. 2021. eLife. 10:00. PubMed
  13. Vinogradova EV, et al. 2020. Cell. 182(4):1009-1026.e29. PubMed
  14. Robertson N, et al. 2020. J Biol Chem. . PubMed
  15. Ho CH, et al. 2021. Arthritis Res Ther. 23:199. PubMed
  16. Cohen CA, et al. 2021. Nat Commun. 12:4678. PubMed
  17. Robertson N, et al. 2020. J Biol Chem. 295:18436. PubMed
  18. Zhou X, et al. 2021. J Clin Transl Hepatol. 9:283. PubMed
  19. Zirngibl F, et al. 2021. J Immunother Cancer. 9:. PubMed
  20. Fang F, et al. 2021. Cell Rep. 37:109981. PubMed
  21. Khanam A, et al. 2021. Front Immunol. 11:599648. PubMed
  22. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
  23. Demaret J, et al. 2021. Front Immunol. 12:778679. PubMed
  24. Cluff E, et al. 2022. Cancer Immunol Immunother. . PubMed
  25. Okoye AA, et al. 2022. PLoS Pathog. 18:e1010245. PubMed
  26. Ferry GM, et al. 2022. Front Immunol. 13:863155. PubMed
  27. Vinogradova EV, et al. 2021. STAR Protoc. 2:100458. PubMed
  28. González-Jiménez A, et al. 2022. Int J Mol Sci. 23: . PubMed
  29. Fosdick MG, et al. 2022. Sci Rep. 12:13506. PubMed
  30. Rydyznski Moderbacher C, et al. 2022. J Clin Invest. :. PubMed
  31. Ledderose C, et al. 2021. J Leukoc Biol. 109:497. PubMed
  32. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  33. Alkasalias T, et al. 2022. Cell Death Discov. 8:464. PubMed
  34. Koutsakos M, et al. 2022. Immunity. 55:1316. PubMed
  35. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  36. Sharma AL, et al. 2022. iScience. 25:105651. PubMed
  37. Lam W, et al. 2023. Front Pharmacol. 13:1095186. PubMed
  38. Larivière L, et al. 2023. Int J Pharm X. 5:100157. PubMed
  39. Miller CL, et al. 2022. Cell Chem Biol. 29:451. PubMed
  40. Fahad AS, et al. 2022. Protein Eng Des Sel. 35:. PubMed
  41. Yen M, et al. 2022. Cell. 185:1414. PubMed
  42. Terahara K, et al. 2022. iScience. 25:104959. PubMed
  43. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  44. Lah S, et al. 2023. J Immunother Cancer. 11:. PubMed
  45. Preglej T, et al. 2023. Front Immunol. 14:1096096. PubMed
  46. Pfister F, et al. 2023. Methods Mol Biol. 2644:331. PubMed
  47. Taylor J, et al. 2023. Front Immunol. 14:1119350. PubMed
RRID
AB_314838 (BioLegend Cat. No. 310903)
AB_314839 (BioLegend Cat. No. 310904)

Antigen Details

Structure
C-type lectin, type II glycoprotein, 28/32 kD
Distribution

Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

Function
Lymphocyte, monocyte, and platelet activation, NK cell killing
Cell Type
B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID
969 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org
Go To Top Version: 1    Revision Date: 11.30.2012

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account